DVAX
Dynavax Technologies Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$15.50
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 330.5M | 277.2M | 232.3M | 722.7M | 439.4M |
| Cost of Revenue | 55.6M | 49.4M | 50.2M | 262.2M | 173.6M |
| Gross Profit | 274.9M | 227.8M | 182.1M | 460.5M | 265.9M |
| Operating Expenses | |||||
| R&D Expense | 73.8M | 61.5M | 54.9M | 46.6M | 32.2M |
| SG&A Expense | 179.7M | 170.4M | 152.9M | 131.4M | 100.2M |
| General & Admin Expense | 179.7M | 170.4M | 152.9M | 131.4M | 100.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 11.0M | — | 11.3M | (1.0M) | (1.0M) |
| Total Operating Expenses | 264.5M | 231.9M | 219.1M | 177.0M | 131.4M |
| Cost and Expenses | 320.1M | 281.4M | 269.3M | 439.2M | 305.0M |
| Operating Income (EBIT) | 10.4M | (4.1M) | (37.0M) | 283.5M | 134.5M |
| Non-Operating | |||||
| Interest Income | 29.5M | 36.5M | 32.0M | 7.9M | 140.0K |
| Interest Expense | 6.4M | 6.8M | 6.8M | 6.7M | 11.2M |
| Net Interest Income | 23.1M | 29.7M | 25.2M | 1.2M | (11.0M) |
| Other Non-Op Income/Expense | (51.0M) | 35.0M | 32.7M | 10.8M | (57.0M) |
| Non-Operating Income (excl Interest) | 44.3M | (41.8M) | (39.4M) | (17.5M) | 45.8M |
| EBT (Pre-Tax Income) | (40.6M) | 30.9M | (4.4M) | 294.3M | 77.5M |
| Income Tax Expense | 2.8M | 3.5M | 2.0M | 1.1M | 808.0K |
| Bottom Line | |||||
| Net Income | (43.4M) | 27.3M | (6.4M) | 293.2M | 76.7M |
| Earnings from Cont. Ops | (43.4M) | 27.3M | (6.4M) | 293.2M | 76.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.2M) | 27.3M | (6.4M) | 296.4M | 75.7M |
| Per Share | |||||
| Basic EPS | ($0.32) | $0.21 | ($0.05) | $2.32 | $0.62 |
| Diluted EPS | ($0.37) | $0.20 | ($0.05) | $1.97 | $0.57 |
| Revenue Per Share | $2.82 | $2.13 | $1.80 | $5.72 | $3.78 |
| Shares | |||||
| Basic Shares Outstanding | 117.3M | 130.0M | 128.7M | 126.4M | 116.3M |
| Diluted Shares Outstanding | 136.5M | 133.3M | 128.7M | 150.8M | 133.0M |
| Profitability Metrics | |||||
| EBITDA | (25.6M) | 45.7M | 9.7M | 307.7M | 95.8M |
| D&A | 8.2M | 8.1M | 7.3M | 6.7M | 7.1M |
| EBIT | (33.9M) | 37.6M | 2.4M | 301.0M | 88.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025